Difference between revisions of "Salgia R, et al. Lung Cancer (2017) cited as Ref 634 in DOI: 10.1038/s41392-020-0110-5 (Q9897)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 105, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer, #quickstatements; #temporary_batch_1590010982689) |
||
| Property / title | |||
| + | A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer (English) | ||
| Property / title: A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer (English) / rank | |||
| + | Normal rank | ||
Revision as of 22:05, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Salgia R, et al. Lung Cancer (2017) cited as Ref 634 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Salgia R
0 references
2017
0 references
Lung Cancer
0 references
105
0 references
A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer (English)
0 references
